Ozanimod
|
|
- CAS-Nr.
- 1306760-87-1
- Englisch Name:
- Ozanimod
- Synonyma:
- (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile;RPC1063;Ozanimod (RPC1063);Ozamud;CS-2386;Ozanimod;Ozanimod-d6;RPC1063 Ozanimod;oxanimod(RPC1063);Ozanimod USP/EP/BP
- CBNumber:
- CB42716147
- Summenformel:
- C23H24N4O3
- Molgewicht:
- 404.46
- MOL-Datei:
- 1306760-87-1.mol
|
Ozanimod Eigenschaften
- Schmelzpunkt:
- 134-137°C
- Siedepunkt:
- 648.3±65.0 °C(Predicted)
- Dichte
- 1.30±0.1 g/cm3(Predicted)
- storage temp.
- -20°C Freezer
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 14.73±0.10(Predicted)
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
Bildanzeige (GHS) |
|
Alarmwort |
Achtung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H372 |
Schädigt bei Hautkontakt und Verschlucken die Organe bei längerer oder wiederholter Exposition. |
Spezifische Zielorgan-Toxizität (wiederholte Exposition) |
Kategorie 1 |
Achtung |
src="/GHS08.jpg" width="20" height="20" /> |
P260, P264, P270, P314, P501 |
|
Sicherheit |
P260 |
Dampf/Aerosol/Nebel nicht einatmen. |
P264 |
Nach Gebrauch gründlich waschen. |
P264 |
Nach Gebrauch gründlich waschen. |
P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
P314 |
Bei Unwohlsein ärztlichen Rat einholen / ärztliche Hilfe hinzuziehen. |
P501 |
Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Ozanimod Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Ozanimod is a sphingosine-1-phosphate receptor 1 (S1P
1) and S1P
5 agonist. It induces GTPγS binding in cell membranes expressing human S1P
1 or S1P
5 (EC
50s = 0.41 and 11 nM, respectively) but not cell membranes expressing S1P
2 or S1P
3 receptors (EC
50s = >10,000 nM for both). Ozanimod (0.2 mg/kg) reduces the number of peripheral lymphocytes in rats. It reduces disease severity and the number of circulating lymphocytes in a mouse model of experimental autoimmune encephalomyelitis (EAE). Ozanimod (0.3 and 1 mg/kg) reduces disease severity and body weight loss in a mouse model of TNBS-induced colitis. Formulations containing ozanimod have been used in the treatment of relapsing multiple sclerosis and ulcerative colitis.
Verwenden
Ozanimod is an agonist that binds to S1P1 and S1P5 receptors. Experiments on rodents revealed that Ozanimod is effective against autoimmune diseases.
Enzyminhibitor
This orally available S1PR1 modulator (FW = 404.46 g/mol; CAS 1306760- 87-1; Solubility: 81 mg/mL DMSO; < 1 mg/mL H2O), also named RPC1063 and 5-[3-[(1S)-2,3-dihydro-1-[(2-hydroxyethyl)amino]-1H-inden- 4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile, selectively targets sphingosine 1-Phosphate (S1P) receptors, which mediate multiple processes, including lymphocyte trafficking, cardiac function, and endothelial barrier integrity. Ozanimod is specific for S1P1R (IC50 = 0.4 nM) and S1P5R, inducing S1P1R internalization and reversibly reducing the number of circulating B and CCR7+ T lymphocytes in vivo. It shows high oral bioavailability and volume of distribution, and a circulatory half-life that supports once daily dosing. Oral ozanimod reduced inflammation and disease parameters in three autoimmune disease models, commending its use in the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Indeed, the safety and efficacy of this modulator ozanimod in relapsing multiple sclerosis is indicated on the basis of a randomized, placebo-controlled, Phase 2 trial. Other SIPR1-directed immunomodulators include laquinimod, ponesimod, and siponimod.
Ozanimod Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Ozanimod Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 191)Lieferanten
- Benzonitrile, 5-[3-[(1S)-2,3-dihydro-1-[(2-hydroxyethyl)aMino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-Methylethoxy)- (free base)
- Ozanimod
- Benzonitrile, 5-[3-[(1S)-2,3-dihydro-1-[(2-hydroxyethyl)amino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)-
- 5-[3-[(1S)-2,3-Dihydro-1-[(2-hydroxyethyl)amino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile
- oxanimod(RPC1063)
- RPC1063 Ozanimod
- CS-2386
- RPC1063;RPC-1063;RPC 1063
- Ozanimod USP/EP/BP
- Ozanimod-d6
- Ozanimod (RPC1063)
- RPC1063
- (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile
- Benzonitrile, 5-[3-[(1S)-2,3-dihydro-1-[(2-hydroxyeth
- Ozamud
- 1306760-87-1
- 13067-87-1
- api